Brief: Neurosense Says Phase 2 Alzheimer's Study Expected To Enroll First Patient In Next Several Weeks

Neurosense Therapeutics

17/10/2023 15:09

Oct 17 (Reuters) - Neurosense Therapeutics Ltd  NRSN.O :
    * NEUROSENSE CEO PROVIDES Q3 2023 UPDATE
    * NEUROSENSE THERAPEUTICS LTD - PHASE 2 ALZHEIMER'S DISEASE
STUDY
IS EXPECTED TO ENROLL FIRST PATIENT IN NEXT SEVERAL WEEKS
    * NEUROSENSE THERAPEUTICS LTD - COMPANY IS FULLY FUNDED INTO
Q2
2024 BEYOND CLINICAL PHASE 2B ALS RESULTS EXPECTED Q4 2023

Source text for Eikon:  ID:nPnbtfYbga 
Further company coverage:  NRSN.O 

 ((Reuters.Briefs@thomsonreuters.com;))